WO2002004605A2 - Stimulation of cellular regeneration and differentiation in the inner ear - Google Patents

Stimulation of cellular regeneration and differentiation in the inner ear Download PDF

Info

Publication number
WO2002004605A2
WO2002004605A2 PCT/US2001/021793 US0121793W WO0204605A2 WO 2002004605 A2 WO2002004605 A2 WO 2002004605A2 US 0121793 W US0121793 W US 0121793W WO 0204605 A2 WO0204605 A2 WO 0204605A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
inner ear
cell
brdu
sensory hair
Prior art date
Application number
PCT/US2001/021793
Other languages
English (en)
French (fr)
Other versions
WO2002004605A3 (en
Inventor
Jonathan Kil
Rendu Gu
Corinne Grigeur
Hubert Lowenheim
Original Assignee
Sound Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Incorporated filed Critical Sound Pharmaceuticals Incorporated
Priority to AU2001288219A priority Critical patent/AU2001288219C1/en
Priority to AU8821901A priority patent/AU8821901A/xx
Priority to JP2002509459A priority patent/JP2004502785A/ja
Priority to CN018126065A priority patent/CN1441841B/zh
Priority to EP01967939A priority patent/EP1307542A2/en
Priority to CA2412764A priority patent/CA2412764C/en
Priority to KR1020037000388A priority patent/KR100896489B1/ko
Publication of WO2002004605A2 publication Critical patent/WO2002004605A2/en
Publication of WO2002004605A3 publication Critical patent/WO2002004605A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Definitions

  • the present invention relates to methods and compositions for stimulating the formation of inner ear cells, including inner ear sensory hair cells and inner ear support cells.
  • SNHL Sensorineuronal hearing loss
  • SNHL Sensorineuronal hearing loss
  • the inner ear includes three sensory portions: the cochlea, which senses sound; the semicircular canals, which sense angular acceleration; and the otolithic organs, which sense linear acceleration.
  • specialized sensory hair cells are arrayed upon one or more layers of inner ear supporting cells. Supporting cells underlie, at least partially surround, and physically support sensory hair cells within the inner ear. In operation, the sensory hair cells are physically deflected in response to sound or motion, and their deflection is transmitted to nerves which send nerve impulses to the brain for processing and interpretation.
  • Sensorineuronal hearing loss can be caused by a multitude of events including age-related loss (presbycusis), noise exposure, drug exposure (e.g., antibiotics and anti-cancer therapeutics), infections, genetic mutations (syndromic and non-syndromic) and autoimmune disease.
  • the present inventors have discovered that destruction of existing inner ear sensory hair cells promotes the re-entry of normally quiescent inner ear supporting cells (that express reduced levels of one or more cell cycle inhibitor proteins, or in which cell cycle protein activity has been reduced) into the cell cycle to yield progeny cells that can be induced to form inner ear sensory hair cells, as disclosed herein.
  • destruction of existing inner ear sensory hair cells is sufficient to stimulate underlying and/or surrounding inner ear support cells to develop into sensory hair cells.
  • efficient regeneration of sensory hair cells from support cells requires destruction of existing inner ear sensory hair cells in combination with at least one other stimulus, as described herein.
  • stimulating the proliferation of inner ear support cells improves the auditory function of the inner ear.
  • the present invention provides methods for stimulating the formation of imier ear cells, including inner ear sensory hair cells and inner ear support cells.
  • the methods of the present invention rely on the unexpected observation that damaging and/or killing inner ear cells stimulates the formation of new, inner ear cells.
  • the present invention provides methods for stimulating the formation of inner ear sensory hair cells from inner ear support cells.
  • the methods of this aspect of the present invention include the step (a) of damaging one or more inner ear sensory hair cells under conditions that promote the formation of one or more new sensory hair cells from one or more support cells that are in contact with the damaged sensory hair cell(s).
  • a plurality of inner ear sensory hair cells are formed from a plurality of inner ear support cells.
  • the methods of this aspect of the invention optionally include the step (b) of further stimulating the formation of one or more inner ear sensory hair cells from inner ear support cells that are in contact with the damaged inner ear sensory hair cell.
  • Step (b) can occur before, during, after or overlapping with step (a).
  • the step of stimulating the formation of one or more inner ear sensory hair cells from one or more inner ear support cells that are in contact with the damaged inner ear sensory hair cell includes the steps of stimulating the inner ear support cells to enter the cell cycle, then stimulating at least some of the progeny of the inner ear support cells to differentiate to form inner ear sensory hair cells.
  • Inner ear sensory hair cells can be damaged, for example, by contact with an amount of an ototoxic agent, such as an antibiotic, preferably an aminoglycoside antibiotic, that is effective to damage inner ear sensory hair cells.
  • an ototoxic agent such as an antibiotic, preferably an aminoglycoside antibiotic
  • the ototoxic agent can be introduced into the inner ear by any art-recognized means, for example by injection (such as with a needle and syringe), or through a cannula.
  • inner ear sensory hair cells are sufficiently damaged to cause their death.
  • damage inflicted on an inner ear sensory hair cell stimulates the formation of one or more new inner ear sensory hair cell from an inner ear support cell that is in contact with the damaged inner ear sensory hair cell.
  • the formation of inner ear sensory hair cells from inner ear support cells is stimulated by damaging inner ear sensory hair cells and expressing within inner ear support cells (before, during and/or after the step of damaging sensory hair cells) a transcription factor capable of stimulating inner ear sensory hair cells to form from inner ear support cells.
  • a nucleic acid molecule encoding a transcription factor capable of stimulating inner ear sensory hair cells to form from inner ear support cells is introduced into inner ear support cells under conditions that enable expression of the transcription factor.
  • transcription factors capable of stimulating the formation of inner ear sensory hair cells from inner ear support cells include POU4F1, POU4F2, POU4F3, Brn3a, Brn3b and Brn3c.
  • the formation of inner ear sensory hair cells from inner ear support cells is stimulated by damaging inner ear sensory hair cells and inhibiting (before, during and/or after the step of damaging the sensory hair cells) the expression of one or more cell cycle inhibitors active in inner ear support cells.
  • Inhibitors of cell cycle inhibitors can be substances, such as proteins, that act on the cell cycle inhibitor directly or indirectly within the cell.
  • cell cycle inhibitors active in inner ear support cells include cyclin-dependent kinase inhibitors, such as cyclin- dependent kinase inhibitors of the so-called CIP/KIP family including p21 C ⁇ pl , p27 K ⁇ pl and p57 Klp2 .
  • the expression of a cell cycle inhibitor active in inner ear support cells can be inhibited by introducing into inner ear support cells an expression vector that expresses a nucleic acid molecule that hybridizes under stringent conditions (such as stringency greater than 2xSSC at 55°C) to a nucleic acid molecule (such as an mRNA molecule) encoding a cell cycle inhibitor active in inner ear support cells.
  • a nucleic acid molecule that hybridizes under stringent conditions (such as stringency greater than 2xSSC at 55°C) to a nucleic acid molecule (such as an mRNA molecule) encoding a cell cycle inhibitor active in inner ear support cells.
  • various recombinant growth factors such as TGF-alpha, insulin and IGF-1 can be used to stimulate the formation of inner ear sensory hair cells from inner ear support cells.
  • a representative, effective concentration range for recombinant growth factors- utilized in vitro in the practice of the present invention is 1-1000 ng/ml. More specifically, TGF-alpha is preferably used at an effective concentration of from 1-100 ng/ml; insulin is preferably used at an effective concentration of from 100-1000 ng/ml; and IGF-1 is preferably used at an effective concentration of from 10-1000 ng/ml. For in vivo applications, a sufficient amount of recombinant growth factor would be administered to produce the foregoing concentrations in vivo.
  • the formation of inner ear sensory hair cells from inner ear support cells results in improvement in the auditory function of the treated inner ear.
  • the invention provides methods for improving auditory function in an inner ear comprising the steps of: (a) damaging a first inner ear sensory hair cell under conditions that promote the formation of one or more new inner ear sensory hair cells from a support cell that is in contact with the damaged, first inner ear sensory hair cell; and (b) measuring an improvement in auditory function in the inner ear treated in accordance with step (a).
  • the present invention provides methods for stimulating the formation of inner ear support cells.
  • the methods of this aspect of the invention include the steps of damaging inner ear support cells under conditions that promote the formation of new inner ear support cells (for example by cell division of inner ear support cells that are in contact with damaged inner ear support cells).
  • the inner ear support cell is damaged, and the formation of new inner ear support cells is stimulated, using the same techniques described herein for the methods of the present invention that stimulate the formation of inner ear sensory hair cells from inner ear support cells.
  • inner ear support cells can be damaged by contact with an amount of an ototoxic agent, such as an aminoglycoside antibiotic, that is effective to damage inner ear support cells.
  • new inner ear support cell formation can be further stimulated by damaging inner ear support cells and expressing (before, during and/or after damaging inner ear support cells) within inner ear support cells a transcription factor (such as POU4F1, POU4F2, POU4F3, Brn3a, Brn3b and Brn3c) capable of stimulating inner ear support cells to divide and form new inner ear support cells.
  • a transcription factor such as POU4F1, POU4F2, POU4F3, Brn3a, Brn3b and Brn3c
  • the proliferation of inner ear support cells results in improvement in the auditory function of the treated inner ear.
  • the methods of the present invention are useful for stimulating the formation of inner ear cells, such as sensory hair cells and support cells. Further, the methods of the present invention are useful to ameliorate the symptoms of a hearing disorder in a mammal, such as a human, that is caused by the death or damage of inner ear cells. Additionally, the methods of the present invention can be used to identify genes and/or proteins that are capable of stimulating the formation of inner ear support cells and/or the formation of inner ear sensory hair cells from inner ear support cells.
  • FIGURE 1 shows a cross section of the Organ of Corti.
  • FIGURE 2 shows the number of BrdU-labeled, guinea pig JH4 cells following serum deprivation for 24 hours and a BrdU pulse for the last 4 hours of the 24 hour period. Cells were counted under fluorescence microscopy. The combination of lipids and p27 k ⁇ pl AS reversed growth arrest to 40% of that seen with 10% FBS stimulation (p ⁇ 0001). (+) FBS; (-) no FBS; (AS) antisense oligonucleotide; (lipid) lipofection.
  • FIGURE 3 shows the ABR threshold of the right ears of mice two weeks after the inner ears of the mice had been treated with amikacin sulfate.
  • Abbreviations are: ABR, auditory brainstem response; dB, decibels; SPL, sound pressure level; Wt, wild type; Het, p27 heterozygote; Ko, p27 knock-out; kHZ, kilo Hertz.
  • FIGURE 4 shows the ABR threshold of the left ears of mice two weeks after the inner ears of the mice had been treated with amikacin sulfate. Abbreviations are the same as those set forth in the description of FIGURE 3.
  • FIGURE 5 shows the ABR threshold of the right ears of mice four weeks after the inner ears of the mice had been treated with amikacin sulfate. Abbreviations are the same as for FIGURE 3.
  • FIGURE 6 shows the ABR threshold of the left ears of mice four weeks after the inner ears of the mice had been treated with amikacin sulfate. Abbreviations are the same as for FIGURE 3. Detailed Description of the Preferred Embodiment
  • SSC refers to a buffer used in nucleic acid hybridization solutions.
  • 20X (twenty times concentrate) stock SSC buffer solution pH 7.0
  • pH 7.0 a stock SSC buffer solution
  • the phrase “damaging one or more inner ear sensory hair cells”, or “damaging a first inner ear sensory hair cell”, or grammatical equivalents thereof, means causing a deleterious change in the structure, biochemistry and/or physiology of the damaged, sensory hair cell (including killing the damaged cell) compared to an inner ear sensory hair cell that is cultured under substantially the same conditions as the damaged cell, but which is not damaged.
  • the phrase “improving auditory function” or “improvement in auditory function”, or grammatical equivalents thereof means improving, by at least
  • the sensitivity to sound of an inner ear by treating the inner ear in accordance with the methods of the present invention, or effecting any measurable improvement in the sensitivity to sound of an inner ear that is completely unresponsive to sound prior to treatment in accordance with the present invention.
  • the sensitivity to sound of the treated inner ear is measured by any art-recognized means (such as the auditory brainstem response) and compared to the sensitivity to sound of a control inner ear that is not treated in accordance with the present invention and which is cultured under substantially the same conditions as the treated inner ear.
  • sequence homology As applied to nucleic acid sequence comparisons or amino acid sequence comparisons herein, the term “sequence homology” (also referred to as “sequence identity”) is defined as the percentage of amino acid residues or nucleic acid residues in a subject amino acid sequence or nucleic acid sequence that are identical with part or all of a candidate amino acid sequence or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology (identity), and not considering any conservative substitutions as part of the sequence homology. Neither N- or C- terminal extensions nor insertions shall be construed as reducing homology. No weight is given to the number or length of gaps introduced, if necessary, to achieve the maximum percent homology (identity).
  • the present invention provides methods for stimulating the formation of inner ear sensory hair cells from inner ear support cells.
  • the methods of this aspect of the present invention include the step (a) of damaging one or more inner ear sensory hair cells under conditions that promote the formation of one or more new sensory hair cells from one or more support cells that are in contact with the damaged sensory hair cell(s).
  • a plurality of inner ear sensory hair cells are formed from a plurality of inner ear support cells.
  • the methods of this aspect of the invention optionally include the step (b) of further stimulating the formation of one or more inner ear sensory hair cells from inner ear support cells that are in contact with the damaged inner ear sensory hair cell.
  • Step (b) can occur before, during, after or overlapping with step (a).
  • the methods of this aspect of the present invention can.be utilized in vivo and in vitro.
  • the cochlea includes the Organ of Corti which is primarily responsible for sensing sound.
  • the Organ of Corti 10 includes a basilar membrane 12 upon which are located a variety of supporting cells 14, including border cells 16, inner pillar cells 18, outer pillar cells 20, inner phalangeal cells 22, Dieter's cells 24 and Hensen's cells 26.
  • Supporting cells 14 support inner hair cells 28 and outer hair cells 30.
  • Tectorial membrane 32 is disposed above inner hair cells 28 and outer hair cells 30.
  • the present invention is adapted, in one aspect, to stimulate regeneration of sensory hair cells 28 and 30 from underlying supporting cells 14. In another aspect, the present invention is adapted to stimulate the formation of supporting cells 14.
  • the present inventors have observed that destruction of existing inner ear sensory hair cells promotes the re-entry of normally quiescent inner ear supporting cells into the cell cycle to yield progeny cells that can be induced to form inner ear sensory hair cells as disclosed herein. In some instances, destruction of existing inner ear sensory hair cells is sufficient to stimulate underlying and/or surrounding inner ear support cells to develop into sensory hair cells. In other instances, efficient regeneration of sensory hair cells from support cells requires destruction of existing inner ear sensory hair cells in combination with another stimulus, as described herein.
  • inner ear sensory hair cells are damaged, for example by contact with an amount of an ototoxic agent that is effective to damage inner ear sensory hair cells.
  • ototoxic agents useful for damaging inner ear sensory hair cells include aminoglycoside antibiotics (such as, neomycin, gentamycin, streptomycin, kanamycin, amikacin and tobramycin).
  • aminoglycoside antibiotics such as, neomycin, gentamycin, streptomycin, kanamycin, amikacin and tobramycin.
  • the foregoing aminoglycoside antibiotics are typically used in vitro at an effective concentration in the range of from about 0.01 mM-10mM, and in vivo at an effective concentration in the range of from about 100 to about 1 ,000 milligrams per kilogram body weight per day (mg/kg/d).
  • Additional, representative examples of chemical agents useful for damaging inner ear sensory hair cells include the following anti-cancer agents: cisplatin, carboplatin and methotrexate which are typically used in vitro at an effective concentration in the range of from about 0.01-0.1 mM, and in vivo at an effective concentration in the range of from about 5 to about 10 mg/kg/d.
  • Other useful chemical agents include poly-L-lysine at an effective concentration in the range of from about 0.1-1.0 mM in vitro, and magnesium chloride at an effective concentration in vitro in the range of from about 5-100 mM.
  • the ototoxic agent, or agents can be introduced into the inner ear by any art- recognized means, for example by injection using a needle and syringe, or by cochleostomy.
  • Cochleostomy involves puncturing the cochlea and inserting a catheter through which a chemical agent can be introduced into the cochlea.
  • a cochleostomy method is disclosed, for example, in Lalwani, A.K. et al., Hearing Research 114: 139-147 (1997), which publication is incorporated herein by reference.
  • the formation of inner ear sensory hair cells from inner ear support cells is stimulated by damaging inner ear sensory hair cells and expressing (before, during, and/or after damaging the inner ear sensory hair cells) within at least some of the inner ear support cells a transcription factor capable of stimulating the formation of an inner ear sensory hair cell from an inner ear support cell.
  • a transcription factor capable of stimulating the formation of an inner ear sensory hair cell is introduced into inner ear support cells under conditions that enable expression of the transcription factor.
  • Transcription factors useful in this aspect of the present invention have the ability to stimulate regeneration of inner ear sensory hair cells from inner ear supporting cells when utilized in the practice of the methods of the present invention. Some transcription factors useful in this aspect of the present invention are required for the normal development, and/or for the normal functioning, of inner ear sensory hair cells.
  • transcription factors useful in this aspect of the present invention include POU4F1 (Collum, R.G. et al., Nucleic Acids Research 20(18): 4919-4925 (1992)), POU4F2 (Xiang et al., Neuron 11: 689-701 (1993)), POU4F3 (Vahava, O., Science 279(5358): 1950-1954 (1998), Brn3a (also known as Brn3.0), Brn3b (also known as Brn3.2) and Brn3c (also known as Brn3.1) as disclosed in Gerrero et al., Proc. Nat'l. Acad. Sci.
  • the term "homeodomain” means an amino acid sequence that is at least 50% homologous (such as at least 75% homologous, or at least 90% homologous) to the homeodomain amino acid sequence set forth in SEQ ID NO:l.
  • the term "POU-specific domain” means an amino acid sequence that is at least 50% homologous (such as at least 75% homologous, or at least 90% homologous) to the POU-specific domain amino acid sequence set forth in SEQ ID NO :2.
  • An example of an algorithm that can be used to determine the percentage homology between two protein sequences, or between two nucleic acid sequences, is the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci.
  • POU4F3 transcription factor homologues are POU4F3 transcription factor homologues (hereinafter referred to as POU4F3 homologues).
  • POU4F3 homologues useful in the practice of the present invention are capable of stimulating the regeneration of inner ear sensory hair cells from supporting cells and are at least 25% homologous (such as at least 50% homologous or at least 75% homologous, or at least 90% homologous) to the POU4F3 transcription factor having the amino acid sequence set forth in SEQ ID NO:4 and which is encoded by the nucleic acid molecule of SEQ ID NO:3.
  • POU4F3 homologues includes the POU4F3 protein having the amino acid sequence set forth in SEQ ID NO:4, which is the presently most preferred inner ear cell transcription factor useful in the practice of the present invention.
  • Representative examples of other POU4F3 homologues useful in the practice of the present invention are set forth in Xiang, M. et al., J. Neuroscience, 15 (7): 4762-4785 (1995), which publication is incorporated herein by reference. Additional nucleic acid molecules encoding transcription factors useful in the practice of the present invention can be isolated by using a variety of cloning techniques known to those of ordinary skill in the art.
  • cloned POU4F3 homologues cDNAs or genes, or fragments thereof can be used as hybridization probes utilizing, for example, the technique of hybridizing radiolabeled nucleic acid probes to nucleic acids immobilized on nitrocellulose filters or nylon membranes as set forth at pages 9.52 to 9.55 of Molecular Cloning, A Laboratory Manual (2nd edition), J. Sambr ok, E.F. Fritsch and T. Maniatis eds., the cited pages of which are incorporated herein by reference.
  • Presently preferred hybridization probes for identifying additional nucleic acid molecules encoding POU4F3 homologues are fragments, of at least 15 nucleotides in length, of the cDNA molecule (or its complementary sequence) having the nucleic acid sequence set forth in SEQ ID NO:3, although the complete cDNA molecule having the nucleic acid sequence set forth in SEQ ID NO: 3 is also useful as a hybridization probe for identifying additional nucleic acid molecules encoding POU4F3 homologue.
  • a presently most preferred hybridization, probe for identifying additional nucleic acid molecules encoding POU4F3 homologues is the oHgonucleotide having the nucleic acid sequence 5'-TAG AAG TGC AGG GCA CGC TGC TCA TGG TAT G-3' (SEQ ID NO:5).
  • Exemplary high stringency hybridization and wash conditions useful for identifying (by Southern blotting) additional nucleic acid molecules encoding POU4F3 homologues are: hybridization at 68°C in 0.25 M Na 2 HPO 4 buffer (pH 7.2) containing 1 mM Na EDTA, 20% sodium dodecyl sulfate; washing (three washes of twenty minutes each at 65°C) is conducted in 20 mM Na 2 HPO 4 buffer (pH 7.2) containing 1 mMNa EDTA, 1% (w/v) sodium dodecyl sulfate.
  • Exemplary moderate stringency hybridization and wash conditions useful for identifying (by Southern blotting) additional nucleic acid molecules encoding P.OU4F3 homologues are: hybridization at 45°C in 0.25 M Na 2 HPO 4 buffer (pH 7.2) containing 1 mM Na 2 EDTA, 20% sodium dodecyl sulfate; washing is conducted in 5X SSC, containing 0.1% (w/v) sodium dodecyl sulfate, at 55°C to 65°C.
  • nucleic acid molecules encoding transcription factors useful in the present invention can be isolated by the polymerase chain reaction (PCR) described in 77ze Polymerase Chain Reaction (K.B. Mullis, F. Ferre, R.A.
  • first strand DNA synthesis can be primed using an oligo(dT) primer
  • second strand cDNA synthesis can be primed using an oHgonucleotide primer that corresponds to a portion of the 5'-untranslated region of a cDNA molecule that is homologous to the target DNA molecule.
  • Subsequent rounds of PCR can be primed using the second strand cDNA synthesis primer and a primer that corresponds to a portion of the 3 '-untranslated region of a cDNA molecule that is homologous to the target DNA molecule.
  • PCR reaction conditions for amplifying nucleic acid molecules encoding transcription factors useful in the present invention are as follows.
  • DNA template e.g., up to 1 ⁇ g genomic DNA, or up to 0.1 ⁇ g cDNA
  • 0.1-0.3 mM dNTPs 10 ⁇ l
  • 10 X PCR buffer 10 X PCR buffer contains 500 mM KC1, 15mM MgCl 2 , 100 mM Tris-HCl, pH 8.3
  • 50 pmol of each PCR primer (PCR primers should preferably be greater than 20 bp in length and have a degeneracy of 10 2 to 10 3 ), 2.5 units of Taq DNA polymerase (Perkin Elmer, Norwalk, CT) and deionized water to a final volume of 50 ⁇ l.
  • thermocycler program is run as follows. Denaturation at 94°C for 2 minutes, then 30 cycles of: 94°C for 30 seconds, 47°C to 55°C for 30 seconds, and 72°C for 30 seconds to two and a half minutes.
  • PCR primers will be designed agamst conserved amino acid sequence motifs found in some or all of the known target protein sequences.
  • conserved amino acid sequence motifs against which PCR primers can be designed for cloning additional POU4F3 homologues are the POU-specific domain having the amino acid sequence set forth in SEQ ID NO:2, and the homeodomain having the amino acid sequence set forth in SEQ ID NO:l.
  • nucleic acid molecules encoding transcription factors useful in the practice of the present invention can also be isolated, for example, by utilizing antibodies that recognize transcription factor proteins.
  • Methods for preparing monoclonal and polyclonal antibodies are well known to those of ordinary skill in the art and are set forth, for example, in chapters five and six of Antibodies A Laboratory Manual, E. Harlow and D. Lane, Cold Spring Harbor Laboratory (1988), the cited chapters of which are incorporated herein by reference.
  • antibodies were successfully raised against a fusion protein constructed from the C-terminal end of Brn3 as described in Xiang, M. et al., J Neuroscience 15(7): 4762-4785 (1995) and Xiang, M.
  • Nucleic acid molecules that encode transcription factors useful in the practice of the present invention - can be isolated, for example, by screening expression libraries.
  • a cDNA expression library can be screened using anti-POU4F3 homologue antibodies in order to identify one or more clones that encode a POU4F3 homologue protein.
  • DNA expression library technology is well known to those of ordinary skill in the art. Screening cDNA expression libraries is fully discussed in Chapter 12 of Sambrook, J., Fritsch, E. F. and Maniatis, T.
  • antigen useful for raising antibodies for screening expression libraries can be prepared in the following manner.
  • a full-length cDNA molecule encoding a transcription factor, such as a POU4F3 homologue, (or a cDNA molecule that is not full-length, but which includes all of the coding region) can be cloned into a plasmid vector, such as a Bluescript plasmid (available from
  • E. coli XLI -Blue harboring a Bluescript vector including a cDNA molecule of interest can be grown overnight at 37°C in LB medium containing 100 ⁇ g ampicillin/ml.
  • the chilled sonicate is cleared by centrifugation and the expressed, recombinant protein purified from the supernatant by art-recognized protein purification techniques, such as those disclosed in Methods in Enzymology, Vol. 182, Guide to Protein Purification, Murray P. Deutscher, ed (1990), which publication is incorporated herein by reference.
  • polyclonal antibodies specific for a purified protein can be raised in a New Zealand rabbit implanted with a whiffle ball. One ⁇ g of protein is injected at intervals directly into the whiffle ball granuloma. A representative injection regime is injections (each of 1 ⁇ g protein) at day 1, day 14 and day 35. Granuloma fluid is withdrawn one week prior to the first injection (preimmune serum), and forty days after the final injection (postimmune serum).
  • Sequence variants, produced by deletions, substitutions, mutations and/or insertions, of the transcription factors useful in the practice of the present invention can also be used in the methods of the present invention.
  • the amino acid sequence variants of the transcription factors useful in the practice of the present invention may be constructed by mutating the DNA sequences that encode the wild-type transcription factor proteins, such as by using techniques commonly referred to as site-directed mutagenesis.
  • Nucleic acid molecules encoding the transcription factors useful in the practice of the present invention can be mutated by a variety of PCR techniques well known to one of ordinary skill in the art. (See, for example, the following publications, the cited portions of which are incorporated by reference herein: "PCR Strategies", M.A. Innis, D.H.
  • the two primer system utilized in the Transformer Site-Directed Mutagenesis kit from Clontech may be employed for introducing site-directed mutants into nucleic acid molecules encoding transcription factors useful in the practice of the present invention.
  • two primers are simultaneously annealed to the plasmid; one of these primers contains the desired site-directed mutation, the other contains a mutation at another point in the plasmid resulting in elimination of a restriction site.
  • Second strand synthesis is then carried out, tightly linking these two mutations, and the resulting plasmids are transformed into a mutS strain of E. coli.
  • Plasmid DNA is isolated from the transformed bacteria, restricted with the relevant restriction enzyme (thereby linearizing the unmutated plasmids), and then retransformed into E. coli.
  • This system allows for generation of mutations directly in an expression plasmid, without the necessity of subcloning or generation of single- stranded phagemids.
  • the tight linkage of the two mutations and the subsequent linearization of unmutated plasmids results in high mutation efficiency and allows minimal screening. Following synthesis of the initial restriction site primer, this method requires the use of only one new primer type per mutation site.
  • a set of "designed degenerate" oHgonucleotide primers can be synthesized in order to introduce all of the desired mutations at a given site simultaneously.
  • Transformants can be screened by sequencing the plasmid DNA through the mutagenized region to identify and sort mutant clones. Each mutant DNA can then be fully sequenced or restricted and analyzed by electrophoresis on Mutation Detection Enhancement gel (J.T. Baker) to confirm that no other alterations in the sequence have occurred (by band shift comparison to the unmutagenized control) .
  • the two primer system utilized in the QuikChangeTM Site-Directed Mutagenesis kit from Stratagene may be employed for introducing site-directed mutants into nucleic acid molecules encoding transcription factors useful in the practice of the present invention.
  • Double- stranded plasmid DNA containing the insert bearing the target mutation site, is denatured and mixed with two oUgonucleotides complementary to each of the strands of the plasmid DNA at the target mutation site.
  • the annealed oHgonucleotide primers are extended using Pfu DNA polymerase, thereby generating a mutated plasmid containing staggered nicks.
  • the unmutated, parental DNA template is digested with restriction enzyme Dpnl which cleaves methylated or hemimethylated DNA, but which does not cleave unmethylated DNA.
  • the parental, template DNA is almost always methylated or hemimethylated since most strains of E. coli, from which the template DNA is obtained, contain the required methylase activity.
  • the remaining, annealed vector DNA incorporating the desired mutation(s) is transformed into E. coli.
  • DNA sequence encoding transcription factors useful in the practice of the present invention may be used to generate deletion variants of transcription factors useful in the practice of the present invention, as described in Section 15.3 of Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, New York, NY (1989), incorporated herein by reference. A similar strategy may be used to construct insertion variants, as described in section 15.3 of Sambrook et al., supra.
  • Oligonucleotide-directed mutagenesis may also be employed for preparing substitution variants of transcription factors useful in the practice of the present invention. It may also be used to conveniently prepare the deletion and insertion variants of transcription factors useful in the practice of the present invention. This technique is well known in the art as described by Adelman et al. (DNA 2:183
  • oUgonucleotides of at least 25 nucleotides in length are used to insert, delete or substitute two or more nucleotides in the nucleic acid molecules encoding transcription factors useful in the practice of the present invention.
  • An optimal oHgonucleotide will have 12 to 15 perfectly matched nucleotides on either side of the nucleotides coding for the mutation.
  • the oHgonucleotide is annealed to the single-stranded DNA template molecule under suitable hybridization conditions.
  • a DNA polymerizing enzyme usually the Klenow fragment of E. coli DNA polymerase I, is then added.
  • This enzyme uses the oHgonucleotide as a primer to complete the synthesis of the mutation-bearing strand of DNA.
  • a heteroduplex molecule is formed such that one strand of DNA encodes the wild-type protein inserted in the vector, and the second strand of DNA encodes the mutated form of the protein inserted into the same vector.
  • This heteroduplex molecule is then transformed into a suitable host cell. Mutants with more than one amino acid substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be mutated simultaneously using one oHgonucleotide that codes for all of the- desired amin ⁇ acid substitutions.
  • the amino acids are located some distance from each other (separated by more than ten amino acids, for example) it is more difficult to generate a single oHgonucleotide that encodes all of the desired changes.
  • one of two alternative methods may be employed. In the first method, a separate oHgonucleotide is generated for each amino acid to be substituted.
  • the oUgonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions.
  • An alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type protein DNA is used for the template, an oHgonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated.
  • the second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations.
  • prokaryotes may be used as host cells for the initial cloning steps of transcription factors useful in the practice of the present invention, hey are particularly useful for rapid production of large amounts of DNA, for production of single-stranded DNA templates used for site-directed mutagenesis, for screening many mutants and/or putative inner ear cell transcription factors simultaneously, and for DNA sequencing of the mutants generated.
  • Suitable prokaryotic host cells include E.
  • E. coli K12 strain 94 ATCC No. 31,446
  • E. coli strain W3110 ATCC No. 27,325
  • E. coli XI 776 ATCC No. 31,537
  • E. coli B E. coli B
  • many other strains of E. coli, such as HB101, JM101, NM522, NM538, NM539, and many other species and genera of prokaryotes including bacilli such as Bacillus subtilis, other enterobacteriaceae such as Salmonella typhimurium or Serratia marcesans, and various Pseudomonas species may all be used as hosts.
  • Prokaryotic host cells or other host cells are preferably transformed using the calcium chloride method as described in section 1.82 of Sambrook et al, supra. Alternatively, electroporation may be used for transformation of these cells. Prokaryote transformation techniques are set forth in Dower, W.J., in Genetic Engineering, Principles and Methods, 12:275-296, Plenum Publishing Corp., 1990; Hanahan et al., Meth. En ⁇ yMol, 204:63 (1991).
  • any plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell may also be used to clone, express and/or manipulate nucleic acid molecules encoding transcription factors useful in the practice of the present invention.
  • the vector usually has a replication site, marker genes that provide phenotypic selection in transformed cells, one or more promoters, and a polylinker region containing several restriction sites for insertion of foreign DNA.
  • Plasmids typically used for transformation of E. coli include pBR322, pUC18, pUC19, ⁇ UCI18, pUC119, and Bluescript Ml 3, all of which are described in sections 1.12-1.20 of Sambrook et l., supra.
  • vectors contain genes coding for ampicillin and/or tetracycline resistance which enables cells transformed with these vectors to grow in the presence of these antibiotics.
  • the promoters most commonly used in prokaryotic vectors include the ⁇ -lactamase (penicillinase) and lactose promoter systems (Chang et al. Nature, 375:615 [1978]; Itakura et al., Science, 198:1056 [1977]; Goeddel et al., Nature, 281:544 [1979]) and a tryptophan (trp) promoter system (Goeddel et al., Nucl.
  • the formation of inner ear sensory hair cells from inner ear support cells is stimulated by damaging inner ear sensory hair cells and inhibiting the expression (before, during and/or after damaging the inner ear sensory hair cells) of one or more cell cycle inhibitors active in inner ear support cells.
  • inner ear support cells that are in contact with damaged sensory hair cells can be stimulated to divide and at least some of the resulting progeny form inner ear sensory hair cells.
  • cell cycle inhibitors active in inner ear support cells include cyclin- dependent kinase inhibitors, such as cyclin-dependent kinase inhibitors of the so- called CIP/KIP family including p21 cipl , p27 ⁇ ipl and p57 ⁇ ip2 .
  • cell cycle inhibitors active within inner ear support cells include: p57 ⁇ ip2 (Lee et al., Genes Dev. 9(6): 639-649 (1995)(SEQ ID NO:6)); p27 Ki l (Cell 78(1): 59-66 (1994)(SEQ ID NOS:8 and 9)); p21 cipl (El-Diery et al., Cell 75(4): 817-825 (1993)(SEQ ID NOS:10 and 11)); pl9 Ink 4d (Chan et al., Mol. Cell. Biol. 15(5): 2682-2688 (1995)(SEQ ID NOS:12 and 13)); pl8 Ink 4c (Guan et al, Genes Dev.
  • pl5 Ink 4b Hard and Beach, 371(6494): 257-261 (1994)(SEQ ID NOS:16 and 17)
  • pl6 Ink 4a Sperrano, M. et al, Nature 366(6456): 704-707 (1993)(SEQ ID NOS: 18 and 19)).
  • Nucleic acid molecules that encode cell cycle inhibitors useful in the practice of the present invention hybridize to the antisense strands of any one of the nucleic acid molecules set forth in SEQ ID NOS: 6, 8, 10, 12, 14, 16 and 18 under at least one hybridization stringency greater than 2 X SSC at 55°C, such as 1 X SSC at 60°C, or 0.2 X SSC at 60°C.
  • Inhibitors of cell cycle inhibitors can be substances, such as proteins, that act on the cell cycle inhibitor in an intracellular, direct or indirect manner. Additionally, inhibitors of cell cycle inhibitors can be antisense nucleic acid molecules that are complementary to all or a portion of a nucleic acid molecule (such as an mRNA molecule) that encodes a cell cycle inhibitor protein, and that hybridize to the nucleic acid molecule encoding a cell cycle inhibitor protein under stringent conditions (such as a stringency greater than 2 X SSC at 55°C, e.g. , 1 X SSC at 60°C or 0.2 X SSC at 60°C).
  • stringent conditions such as a stringency greater than 2 X SSC at 55°C, e.g. , 1 X SSC at 60°C or 0.2 X SSC at 60°C.
  • any art-recognized method can be used to inhibit cell cycle inhibitor gene expression in inner ear support cells.
  • the expression of a cell cycle inhibitor active in inner ear support cells can be inhibited by introducing into inner ear support cells a vector that includes a portion (or all) of a nucleic acid molecule, in antisense orientation relative to a promoter sequence, that encodes a cell cycle inhibitor active in inner ear support cells.
  • antisense technology utilizes a DNA sequence that is inverted relative to its normal orientation for transcription and so expresses an RNA transcript that is complementary to a target mRNA molecule expressed within the host cell (i.e., the RNA transcript of the anti-sense gene can hybridize to the target mRNA molecule through Watson-Crick base pairing).
  • An anti-sense gene may be constructed in a number of different ways provided that it is capable of interfering with the expression of a target gene, such as a gene encoding a cell cycle inhibitor.
  • the anti-sense gene can be constructed by inverting the coding region (or a portion thereof) of the target gene relative to its normal orientation for transcription to allow the transcription of its complement, hence the RNAs encoded by the anti-sense and sense gene are complementary.
  • the anti-sense gene generally will be substantially identical to at least a portion of the target gene or genes.
  • the sequence need not be perfectly identical to inhibit expression. Generally, higher homology can be used to compensate for the use of a shorter anti-sense gene.
  • the minimal identity will typically be greater than about 65%, but a higher identity might exert a more effective repression of expression of the endogenous sequences. Substantially greater identity of more than about 80% is preferred, though about 95% to absolute identity would be most preferred.
  • the anti-sense gene need not have the same intron or exon pattern as the target gene, and non-coding segments of the target gene may be equally effective in achieving anti-sense suppression of target gene expression as coding segments.
  • a DNA sequence of at least about 30 or 40 nucleotides should be used as the anti-sense gene, although a longer sequence is preferable.
  • the construct is then introduced into one or more inner ear support cells and the antisense strand of RNA is produced.
  • Catalytic RNA molecules or ribozymes can also be used to inhibit expression of target genes.
  • ribozyme transgenes that encode RNA ribozymes that specifically pair with a target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA.
  • the ribozyme In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules.
  • the inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the antisense constructs. Tabler et al.
  • An additional strategy suitable for suppression of target gene activity entails the sense expression of a mutated or partially deleted form of the protein encoded by the target gene according to general criteria for the production of dominant negative mutations (Herskowitz I, Nature 329: 219-222 (1987)).
  • any art-recognized gene delivery method can be used to introduce a nucleic acid molecule encoding a transcription factor (or a vector including an antisense DNA molecule) into inner ear cells for expression therein, including: direct injection, electroporation, virus-mediated gene delivery, amino acid-mediated gene delivery, biolistic gene delivery, lipofection and heat shock.
  • Non-viral methods of gene delivery into inner ear cells are disclosed in Huang, L., Hung, M-C, and Wagner, E., Non- Viral Vectors for Gene Therapy, Academic Press, San Diego, California (1999), which is incorporated herein by reference.
  • genes can be introduced into cells in situ, or after removal of the cells from the body, by means of viral vectors.
  • retroviruses are RNA viruses that have the ability to insert their genes into host cell chromosomes after infection. Retroviral vectors have been developed that lack the genes encoding viral proteins, but retain the ability to infect cells and insert their genes into the chromosomes of the target cell (A.D. Miller, Hum. Gen. Ther. 1:5-14 (1990)).
  • Adeno viral vectors are designed to be administered directly to patients. Unlike retroviral vectors, adenoviral vectors do not integrate into the chromosome of the host cell. Instead, genes introduced into cells using adenoviral vectors are maintained in the nucleus as an extrachromosomal element (episome) that persists for a limited time period. Adenoviral vectors will infect dividing and non-dividing cells in many different tissues in vivo including airway epithelial cells, endothelial cells, hepatocytes and various tumors (B.C. Trapnell, Adv Drug Del Rev. 12:185-199 (1993)). Another viral vector is the herpes simplex virus, a large, double-stranded
  • DNA virus that has been used in some initial applications to deliver therapeutic genes to neurons and could potentially be used to deliver therapeutic genes to some forms of brain cancer (D.S. Latchman, Mol. Biotechnol. 2:179-95 (1994)).
  • Recombinant forms of the vaccinia virus can accommodate large inserts and are generated by homologous recombination.
  • this vector has been used to deliver interleukins (ILs), such as human IL-l ⁇ and the costimulatory molecules B7-1 and B7-2 (G.R. Peplinski et al, Ann. Surg. Oncol. 2:151-9 (1995); J.W. Hodge et al., Cancer Res. 54:5552-55 (1994)).
  • ILs interleukins
  • plasmid DNA is taken up by cells within the body and can direct expression of recombinant proteins.
  • plasmid DNA is delivered to cells in the form of liposomes in which the DNA is associated with one or more lipids, such as DOTMA (l,2,-diolcyloxypropyl-3-trimethyl ammonium bromide) and DOPE (dioleoylphosphatidylethanolamine).
  • DOTMA l,2,-diolcyloxypropyl-3-trimethyl ammonium bromide
  • DOPE dioleoylphosphatidylethanolamine
  • Intramuscular administration of plasmid DNA results in gene expression that lasts for many months (J.A. Wolff et al., Hum. Mol. Genet. 1:363-369 (1992); M. Manthorpe et al, Hum. Gene Ther. 4:419-431 (1993); G. Ascadi et al., New Biol. 3:71-81 (1991), D. Gal et al., Lab. Invest. 68:18-25 (1993)).
  • BiolisticTM a ballistic device that projects DNA-coated micro-particles directly into the nucleus of cells in vivo. Once within the nucleus, the DNA dissolves from the gold or tungsten microparticle and can be expressed by the target cell.
  • This method has been used effectively to transfer genes directly into the skin, liver and muscle (N.S. Yang et al, Proc. Natl. Acad. Sci. 87:9568-9572 (1990); L. Cheng et al., Proc. Natl. Acad. Sci. USA. 90:4455-4459 (1993); R.S. Williams et al., Proc. Natl. Acad. Sci. 88:2726-2730 (1991)).
  • Cochleostomy involves puncturing the cochlea and inserting a catheter through which a chemical agent, such as a nucleic acid molecule, can be introduced into the cochlea.
  • a cochleostomy method is disclosed, for example, in Lalwani, A.K. et al., Hearing Research 114: 139-147 (1997), which publication is incorporated herein by reference.
  • molecular conjugates consist of protein or synthetic ligands to which a nucleic acid- or DNA-binding agent has been attached for the specific targeting of nucleic acids to cells
  • R.J. Cristiano et al Proc. Natl. Acad. Sci. USA 90:11548-52 (1993); B.A. Bunnell et al., Somat. Call Mol. Genet. 18:559-69 (1992); M. Gotten et al., Proc. Natl. Acad. Sci. USA 89:6094-98 (1992)
  • This gene delivery system has been shown to be capable of targeted delivery to many cell types through the use of different ligands (RJ. Cristiano et al., Proc. Natl. Acad. Sci. USA 90:11548-52 (1993)).
  • the vitamin folate has been used as a ligand to promote delivery of plasmid DNA into cells that overexpress the folate receptor (e.g., ovarian carcinoma cells) (S. Gottschalk et al., Gene Ther. 1:185-91 (1994)).
  • the malaria circumsporozoite protein has been used for the liver-specific delivery of genes under conditions in which ASOR receptor expression on hepatocytes is low, such as in cirrhosis, diabetes, and hepatocellular carcinoma (Z.
  • the whole inner ear including the Organ of Corti, is preferably excised and cultured and manipulated in a culture vessel.
  • Presently preferred embodiments of an apparatus that is useful for culturing inner ears in vitro are disclosed in U.S. Patent Serial No: 5,437,998; U.S. Patent Serial No: 5,702,941 and U.S. Patent Serial No: 5,763,279, each of which is incorporated herein by reference.
  • an apparatus for culturing inner ears include a gas permeable bioreactor comprising a tubular vessel with walls that may be constructed at least partially of a gas permeable material, such as silicone rubber.
  • the vessel in one preferred embodiment is constructed such that half of it is comprised of gas permeable material and the remaining . portion is made of nonpermeable material.
  • the gas permeable materials commonly available are opaque.
  • using nonpermeable material for at least part of the bioreactor may provide an advantage in allowing visual inspection of the tubular vessel chamber.
  • the tubular vessel has closed ends, a substantially horizontal longitudinal central axis, and one or more vessel access ports.
  • the vessel access ports provide access to the bioreactor for input of medium and cells, and for removal of old medium from the tubular vessel. This is easily done through the vessel access ports which are also referred to as valves or syringe ports.
  • the vessel access ports are constructed of valves with syringe ports.
  • the vessel is rotatable about its horizontal longitudinal central axis.
  • a preferred means for rotation is a motor assembly which sits on a mounting base and has means for attachment to the tubular vessel. The speed of rotation can be adjusted so that the inner ear within the tubular vessel is constantly in motion, but rotation of the tubular vessel should not be fast enough to cause significant turbulence in the aqueous medium within the tubular vessel.
  • the use of gas permeable material in the construction of at least part of the tubular vessel wall permits O 2 to diffuse through the vessel walls and into the cell culture media in the vessel chamber.
  • CO diffuses through the walls and out of the vessel.
  • gas permeable material in the construction of at least part of the tubular vessel wall typically overcomes the need for air injection into the bioreactor vessel.
  • Air injection into the aqueous medium within the bioreactor vessel may be utilized, however, if additional oxygen is required to culture an inner ear.
  • an air filter is also employed to protect the air pump valves from dirt.
  • An alternative embodiment of the bioreactor useful in the practice of the present invention is an annular vessel with walls that may be constructed at least partially of a gas permeable material.
  • Annular is defined herein to include annular, toroidal and other substantially symmetrical ring-like shaped tubular vessels.
  • the annular vessel has closed ends and a substantially horizontal longitudinal central axis.
  • the bioreactor useful in the practice of the present invention comprises a tubular vessel constructed at least partially of a gas permeable material.
  • the vessel has closed ends and a substantially horizontal longitudinal central axis around which it rotates.
  • the vessel furthermore has two slidably interconnected members wherein a first member fits slidably into a second member, forming a liquid tight seal therebetween and providing a variable volume tubular vessel.
  • the bioreactor has means for rotating the tubular vessel about its substantially horizontal longitudinal central axis.
  • One or more vessel access ports are provided for transferring materials into and out of the vessel. In situations where minimization of contamination is necessary (e.g., AIDS or human tissue research), disposability of the bioreactor useful in the practice of the present invention is a particular advantage.
  • bioreactor with slidably interconnected members may be adjusted to provide the exact size bioreactor needed.
  • bioreactors useful in the practice of the present invention for culturing fluid-filled sensory organs are known as the
  • NeuralbasalTM media from Gibco BRL (Gibco BRL media are produced by Life Technologies, Corporate Headquarters, Gaithersburg, MD), which requires the addition of B27 or N2 media supplement, is the presently preferred culture medium for culturing inner ears in vitro.
  • Other culture media can be successfully used, however, to culture fluid-filled sensory organs in the practice of the present invention.
  • Other suitable media include DME, BME and M-199 with fetal calf serum or horse serum. All of the foregoing media are sold by Gibco -BRL.
  • N2 or B27 supplements play a more significant role when extended periods of culture (>96 hr) are attempted.
  • the present invention provides methods for stimulating the formation of inner ear support cells.
  • the methods of this aspect of the invention include the steps of damaging inner ear support cells under conditions that promote the formation of new inner ear support cells (for example by cell division of inner ear support cells that are in contact with damaged inner ear support cells).
  • the inner ear support cell is damaged, and the formation of new inner ear support cells is stimulated, using the same techniques described herein for the methods of the present invention that stimulate the formation of inner ear sensory hair cells from inner ear support cells.
  • inner ear support cells can be damaged by contact with an amount of an ototoxic agent, such as an aminoglycoside antibiotic, that is effective to damage inner ear support cells.
  • new inner ear support cell formation can be further stimulated by damaging inner ear support cells and expressing (before, during and/or after damaging inner ear support cells) within inner ear support cells a transcription factor (such as POU4F1, POU4F2, POU4F3, Brn3a, Brn3b and Brn3c) capable of stimulating inner ear support cells to divide and form new inner ear support cells.
  • a transcription factor such as POU4F1, POU4F2, POU4F3, Brn3a, Brn3b and Brn3c
  • the proliferation of inner ear support cells results in improvement in the auditory function of the treated inner ear.
  • Example 1 Overexpressing POU4F3 in immortalized supporting-cell lines in vitro.
  • POU4F3 is a DNA binding transcription factor exhibiting remarkable specificity to the hair-cells in the inner ear. Mutations in POU4F3 are known to cause developmental failures in mice, and hearing loss in both mice and humans.
  • the role of POU4F3 in directing the development of hair-cell precursors is investigated by transfecting inner ear supporting-cell lines with POU4F3. To detect the expression of POU4F3 in live cultures, the expression of
  • Enhanced Green Fluorescent Protein translated from a bicistronic mRNA which includes both POU4F3 and GFP coding regions, is monitored. Specifically, a 1250 bp cDNA encoding POU4F3 including 70 bp of 5'UTR and 73 bp of 3' UTR is directionally cloned into the unique EcoRV restriction site of the pIRES2-EGFP vector (Clonetech) directly down stream from the human CMV major immediate early promoter/enhancer. An intervening synthetic intron is cloned downstream from the POU4F3 gene to enhance the stability of the mRNA.
  • pIRES2-EGFP vector Clonetech
  • the internal ribosomal entry site (IRES) from encephelomyocarditis virus is cloned between the POU4F3 gene and the GFP gene to allow for the translation of GFP and POU4F3 protein from the same mRNA.
  • IRS internal ribosomal entry site
  • Immediately following the GFP coding region is a poly- adenylation signal from the bovine growth hormone gene.
  • This expression cassette is designed to take advantage of the bicistronic promoter to allow tracking of transfection and expression of POU4F3 and GFP by visualization of expressed GFP under fluorescence microscopy.
  • the pIRES2 vector utilizes a partially disabled IRES sequence (Rees, S. et al., BioTechniques 20:102110 (1996)). This attenuated IRES leads to a reduced rate of translation initiation at the GFP start codon relative to that of the POU4F3 gene.
  • the supporting-cell line was established from the inner ear vestibular sensory epithelia of the 112k b -tsA 58 transgenic mouse (Immortarnouse). Utricles from postnatal day one mice were dissected and the sensory epithelia (hair-cells and supporting-cells) isolated after brief thermolysin treatment at 37°C. The resultant supporting-cell line was derived after several passages at permissive conditions (33°C and ⁇ lNF) which stimulates rapid cell proliferation. Confluence was achieved in 3-4 days. This process resulted in the death of all hair-cells as determined by ICC and electron microscopy (EM).
  • ICC electron microscopy
  • the UCLs were further characterized by an antibody called ZO-1 (which labels tight junctions that are present in supporting-cells) and EM (which showed tight junction complexes, secretory vesicles and luminal surface microvilli, all characteristic of supporting-cells).
  • Culture medium for the UCL cell line consisted of DMEM/F12 (Gibco), fetal bovine serum (10%) and ⁇ lNF (20 u/ml). Media changes were done 2 to 3 times a week depending on the growth rate of the cells.
  • Single-cell clones were developed using a special seeding method that enabled single cells to become confluent and passageable in 3-4 weeks. At non-permissive conditions (37°C or 39°C, no ⁇ lNF and low or no FBS) cell growth arrests.
  • these cells are grown and passaged in defined media that is serum free. Once this is established, these cells are lipofected with the IRES-GFP-POU4F3 encoding plasmid. Cultures are monitored for GFP expression over 1-6 DIV. When periods of high GFP fluorescence are observed in live cultures, the culture are fixed and prepared for POU4F3 and calbindin ICC.
  • hair-cell selective markers such as myosi ⁇ and myosin 7a using polyclonal antibodies derived against these proteins.
  • hair-cell specific markers such as myosin 6 and 7a are observed in the embryonic mouse organ of Corti at El 6, 2-3 days after the expression of the Brn 3.1 transcription factor begins at El 3.5.
  • Table 1 shows the number of hair cells (n) in four- week old p27 Klpi +/+, +/-, -/- mice. Counts were made from a 100 ⁇ m length of sensory epithelium from three different locations along the longitudinal axis of the organ of Corti. Distance corresponds to degrees from the apical tip of the cochlea ( ⁇ s.d.). Comparisons were made with the same hair cell region across +/+, +/- and -/-. Statistical, significance was determined using ANOVA.
  • HCs were lesioned using systemic injections of amikacin sulfate (P7-P12) and then injected with BrdU (P10-12). Mice were sacrificed either 2 d or 14 d after the last injection. The effects of an amikacin lesioning were at least two-fold. First, in both p27 K ⁇ l -/- and +/- mice, the number of BrdU positive cells increased following amikacin/BrdU vs BrdU alone treatment.
  • the protocol used to measure protein levels in the cochlea is as follows.
  • a cochlea is transferred to a tube with 10 ⁇ l of extraction buffer which contains :HEPES (25 mM), NP-40 (0.7%), Aprotintin (1 mM), Leupeptin (1 ⁇ g/ml), Pepstatin (10 ⁇ M), phenylmethylsulfonylfluoride (PMSF) (1 mM), dithiothreitol (DTT) (1 mM), and ethylenediaminetetraacetic acid (EDTA) (2 mM).
  • the cochlea is homogenized immediately and the tube is placed on ice for about 30 min. Add 5 ⁇ l of 4X sample buffer and adjust the salt concentration up to 0.5 M.
  • mice received systemic injections of amikacin sulfate (500mg/kg/d/s.c) for six consecutive days that were combined with injections of the replication marker, bromodeoxyuridine (BrdU; 30mg/kg/d/s.c) between P10- P12. Mice were also injected with BrdU alone in a similar fashion.
  • mice were then sacrificed 14 d later and the vestibular sensory organs were fixed, dissected and processed for BrdU immunocytochemistry.
  • BrdU positive nuclei were counted from whole mounts using light microscopy and Nomarski optics. Selected organs were further processed for cross section analysis.
  • Table 3 shows the numbers of BrdU labeled cells in the vestibular organs of four-week old p27 Klpl +/+, +/- and -/- mice injected with BrdU or BrdU/Amikacin and after a 14 d recovery. Counts were performed from whole utricular, saccular and cristae sensory epithelium ( ⁇ s.d.). In the BrdU group, statistical significance was determined by comparing proliferation levels in the same sensory organ across +/+, +/- and -/-. In the BrdU/Amikacin group, statistical significance was determined by comparing proliferation levels in the same sensory organ of the same genotype. Statistical significance was determined using ANOVA.
  • FITC-positive supporting cells were detected in 18-24 h and increased in number and fluorescent intensity between 24-48 h. Cultures were aldehyde fixed and processed for BrdU immunocytochemistry. BrdU-positive supporting cells appeared in most cochlear cultures after 24 h of antisense oHgonucleotide (ON) treatment. BrdU-positive doublets appeared in antisense ON treated cultures that were recovered for an additional 24 hr without antisense ONs. This indicated that successful completion of M phase and subsequent cell division could occur. Lipofection-only treated cultures contained very low levels of BrdU-labeled supporting cells.
  • organotypic cultures can be established on glass slides (Nunc) coated with CellTak (Collaborative Research) in 100 ⁇ ls of NeuroBasal media (Gibco) containing 1 mM neomycin. This treatment kills 95 % of the hair cells and also facilitates the level of transfection.
  • Cultures are lipofected with antisense molecules using commercially available lipofection reagents (e.g, Perfect Lipofection Kit; InVitrogen, Inc.).
  • the media also contains BrdU (10 ⁇ M) to identify proliferating cells.
  • various recombinant growth factors such as TGF- alpha (1-100 nM), insulin (10-100 ⁇ M) and IGF-1 (1-100 ⁇ M) can be used to increase or drive this proliferative effect.
  • JH4 guinea pig fibroblast line
  • Antisense Molecules Two ⁇ recent, independent studies indicate that antisense ONs can be successfully delivered through the perilymphatic space and elicit changes in the organ of Corti of mature guinea pigs (D'Aldin, C, et al, Mol. Brain Res., 55: 151- 164 (1998); Leblanc, C.R., et al. Hear. Res., 135: 105-112 (1999)).
  • the presence of FITC-antisense ON against specific sequences to the mRNA of GluR2 was seen in the spiral ganglia, supporting cells, and inner and outer spiral sulcus cells within 24 h after the osmotic pump installation. A subsequent selective decrease in GluR2/3 protein was also observed in situ (D'Aldin et al., 1998, supra).
  • the coil is loaded with the drug and the osmotic minipump carries a dye.
  • the total volume of drug pumped into the inner ear can be monitored by the amount of dye which is pumped into the coil.
  • the drug is dissolved in a solution of artificial perilymph which consists of: 137 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM Hepes, 11 mM Glucose, pH 7.4 and osmolarity 300mOsm/L.
  • the mastoid bulla (middle ear space) is exposed via a post- auricular incision and opened using a 1 mm cutting burr to allow visualization of the basal turn of the cochlea.
  • a cochleostomy about 1 mm inferior to the round window is fashioned using a 0.5 mm diamond paste burr. Observed inner ear perilymph fluid leaking from this site confirms correct positioning of the cochleostomy.
  • the tip of the infusion unit is inserted into the cochleostomy and the tubing is secured on the wall of the middle ear by dental cement.
  • the infusion unit is stored in a subcutaneous pocket created behind the neck.
  • the skin incision is closed in layers with 2-0 silk. This procedure is performed on both ears to avoid any subsequent imbalance or rotational behavior and to reduce the number of animals needed to complete the experiment. The procedure takes approximately 30 minutes per side.
  • the hair cell loss group receives gentamycin sulfate for one week to kill the hair cells with immediate sacrifice and two week recovery. Three concentrations are used that should provide a total loss of HCs as well as a graded loss of HCs. Cationic liposomes in 5% (w/v) dextrose solution are delivered for one to two weeks. The purpose of this group is to see if any damage is caused by lipofection. Lipofection after hair cell loss involves the. substitution of a gentamycin containing pump to a lipid containing pump. Lipofection plus antisense after hair cell loss involves lipofecting FITC-antisense for another week.
  • Lipofection plus antisense plus growth factors after damage are delivered for one week followed by the lipofection of antisense and growth factors for another week.
  • Several groups involve combining antisense with growth factors, including TGF-alpha, insulin, and IGF-1.
  • a separate osmotic pump loaded with BrdU is implanted subcutaneously to allow identification of mitotically active cells
  • Hair cell damage resulting from gentamycin is checked by myosin- Vila immunocytochemistry (a hair cell specific marker) and phalloidin histochemistry (F-actin marker) using a whole mount staining technique.
  • the transfection efficiency of liposome and p27 K ⁇ pl antisense oligonucleotides is assessed by observing for the presence of FITC-labeled nuclei under epifluorescence.
  • BrdU immunohistochemistry is used to determine whether proliferation was induced with p27 ⁇ p antisense ON treatment. Selected specimens are analyzed under electron microscopy.
  • Vlla to assess the number of new supporting cells versus the number of total hair cells.
  • ABR Auditory Brainstem Responses
  • guinea pigs are anesthetized with Avertin (0.2 ml/lOg body weight/i.m. using a 1.2% stock solution).
  • the active electrodes are placed subcutaneously near the external meatus of the ear (0.1 -mm silver wire; Narishige).
  • the dural reference electrode is placed in a drilled hole rostral to the bregma (or an insert earphone into the ear canal and the sound delivery tube secured to the pinna with surgical tape).
  • the ground electrode (Ag/AgCI 2 pellet) is fixed on the back.
  • the sound stimuli is either a broad band click of lOO ⁇ s duration or a 10 ms tone burst (1ms rise/fall time).
  • Guinea pigs are in a sound attenuated chamber (TDT model AC-1). The responses are measured and recorded via an Auditory Evoked Response Workstation (SmartEP; Intelligent Hearing System). Guinea pigs are presented with a stimulus intensity series incremented from 20 to 85 dB in 5 dB steps for both click and tone burst stimuli. For tone bursts, a stimulus frequency series (1, 2, 4, 8, 16, 32 Hz) at a constant intensity of 50 dB is also used. Stimuli are repeated 5 times/s and a total of 512 trials will be averaged. Threshold is defined as the lowest intensity capable of eliciting a replicable and visually detectable ABR.
  • mice were treated the same as the mice described in the experiments reported in Table 2 herein, except that, in the present example, there was an additional recovery time point at four weeks after amikacin treatment.
  • Auditory function was measured using the auditory brainstem response (ABR) using subcutaneous recording electrodes placed on three head points in Isofluorane anesthetized mice.
  • the sound intensity threshold was determined by presenting single frequencies as different sound intensities (intensity measured in decibels). The higher the tone intensity that is required to elicit the ABR, the higher the auditory threshold, i.e., the worse the auditory function.
  • the data set forth in FIGURES 3-6 shows auditory improvement in five out of eight p27 heterozygotes (pO.OOl).
  • Example 9 The lipofection method of gene delivery and gene expression in the mouse organ of Corti culture system.
  • Lipofecting the organ of Corti utilized cochlear explants obtained from postnatal day 7-14 mice grown for a total of up to 8 days in vitro (DIV). Cultures were grown in defined culture media composed of Neurobasal Media with B27 supplement (Gibco). Cultures were exposed to an aminoglycoside antibiotic (1 mM neomycin sulfate for 48 hrs) which selectively killed the inner ear sensory hair-cells. Eight different lipid combinations were then tested from the Perfect Lipofection Kit (InVitrogen). A bacterial plasmid encoding a betagalactosidase reporter gene driven by a CMV immediate/early gene promoter (InVitrogen) was delivered over a 6 hr period.
  • the cultures were aldehyde-fixed and processed for betagalactosidase expression using x-gal histochemistry.
  • X-gal labeling appeared in supporting-cells (54.3 +/- 15.3 labeled cells per lOOO ⁇ m length in the regions of the sensory epithelium that once contained hair-cells, versus 5-10 labeled cells per 1000 ⁇ m length in tissue that had not been lesioned).
  • betagalactosidase encoding construct i.e., 4.1 kbp
  • Detection of GFP requires a standard FITC filter set (excitation maximum 488 nm, emission maximum 509 nm) and has been successfully transfected into cochlear hair- cells, supporting-cells and neurons using an AAV vector system.
  • Organ of Corti cultures established from P7-P14 Swiss Webster mice derived from our breeding colony are lipofected using a variety of commercially available lipofection reagents (i.e., FuGENE Transfection Reagent; Boehringer-Mannheim). These efficiences are compared against the transfection efficiences achieved by the InVitrogen Kit.
  • the superior lipofection reagent and the superior lipid to DNA ratio (3:1, 6:1, 9: 1) are determined by counting the number of GFP-positive cells within the organ of Corti along a 1000 ⁇ m length taken at the middle of the explant. Cells are visualized using a Nikon epifluorescence microscope equipped with a CCD digital camera that outputs images directly into an imaging software program where cell counts are performed.
  • An aminoglycoside antibiotic lesion of the hair-cells is then be combined with subsequent lipofection.
  • Media containing 1 mM neomycin sulfate (Sigma) is administered to kill the hair-cells over a 48 period in culture.
  • the two-week old mouse which has developed auditory function is more easily affected by this concentration of neomycin resulting in a greater than 95% loss of hair-cells as determined by calbindin immunoreactivities and plastic cross-section analysis.
  • the remaining supporting-cells are lipofected for 6 hr with a GFP encoding plasmid. Cultures are rinsed and grown in fresh media for an additional 1-4 DIV for a total of 3-6 DIV.
  • the inner ear of a mouse was excised in the following manner. Postnatal day 7-14 Swiss Webster mice were decapitated and their skulls immersed in 10% ethanol for 5 min to disinfect. Under sterile conditions, the skull was cut into halves along the mid-sagittal axis and placed into 3 ml of culture media (NeuralbasalTM Media at pH 7.4; Gibco) in a 35 mm plastic culture dish (Nalge Nunc International, 2000 North Aurora Road, Naperville, IL 60563). Using surgical forceps, the bony inner ear labyrinth was visualized and separated from the temporal bone. The overlying connective tissue, stapes bone, facial nerve and stapedial artery were removed.
  • an inner ear excised and prepared in the foregoing manner is transferred to the HARVTM or CCCVTM vessel which contains 50 or 55 ml of NeuralbasalTM Media supplemented with either N2 or B27 media supplement (both sold by Gibco-BRL, Catalogue number 17504-036), lO U/ml of penicillin and .25 ⁇ g/ ⁇ l of fungizone.
  • the B27 supplement is sold as a 50X concentrate which is used at a working concentration of 0.5X (e.g., 550 ⁇ l of 50X B27 stock solution is added to 55 ml of NeuralbasalTM Media).
  • the N2 supplement stock solution is 100X and is used at a working concentration of IX (e.g., 550 ⁇ l of 100X N2 stock solution is added to 55 ml of NeuralbasalTM Media).
  • the vessel is then placed in a tissue culture incubator at 37°C and in a 95% air/5% CO 2 environment.
  • the vessel is then rotated at 39 rpm for periods of 24-168 hr. 50% media changes are made every 48 hr. As few as 2 and as many as 12 inner ears have been successfully cultured in one vessel.
  • the inner ear is placed in NeuralbasalTM/N2 or B27 media that contain 1 mM neomycin sulfate (Sigma, P.O. Box 14508, St. Louis, MO 63178) for 24-48 hr. After this culture period, the media is completely replaced with media devoid of neomycin.
  • NeuralbasalTM/N2 or B27 media that contain 1 mM neomycin sulfate (Sigma, P.O. Box 14508, St. Louis, MO 63178) for 24-48 hr. After this culture period, the media is completely replaced with media devoid of neomycin.
  • Table 5 shows the composition of NeuralbasalTM medium (lx) sold by Gibco. All concentrations are working concentrations, i.e., the concentrations of the components in the medium in which the fluid-filled sensory organ is incubated.
  • NeuralbasalTM medium The following antibiotics may be added to NeuralbasalTM medium.
  • Fungizone reagent amphotericin B, 0.25 ⁇ g/ml, and sodium desoxycholate, 0.25 ⁇ g/ml
  • Penicillin G (10 units/ml) which is sold by Sigma, Catalog number P 3414.
  • NeuralbasalTM medium may also be supplemented with L-Glutamine (2mM).
  • Example 12 Assay for Sensory Epithelium Vitality During Long Term Culture
  • the microgravitational environment provided by the rotation of a culture vessel allows the sensory epithelium of the inner ear to be maintained for prolonged periods of culture (>168 hr.) without significant degradation or loss of the sensory hair-cells or non- sensory supporting-cells.
  • Data demonstrating the continued vitality of the sensory hair cells during prolonged culture were obtained by labeling the sensory epithelia with a probe against F-actin (phalloidin-FITC) that labels the surfaces of sensory and non-sensory cells, and with a hair-cell specific antibody against calbindin, a calcium binding protein. Both labels were detected and photographed under epifiuorescence microscopy.
  • F-actin phalloidin-FITC
  • the Organ of Corti has several fluid- filled spaces called the tunnel of Corti and spaces of Nuel that are necessary for normal auditory function. These spaces occur between hair-cells and supporting- cells and are maintained after prolonged periods of culture.
  • the sensory epithelia In normal gravitational environments, (i.e., when the inner ear is floated without rotating the culture vessel) the sensory epithelia begin to degenerate. Without rotation, within 24 hr. the hair- cells are either completely missing or appear to be undergoing various endstages of cell death. After 48 hr., the supporting-cells are completely missing, or are present but with the total loss of the tunnel of Corti and spaces of Nuel. Rotating the vessel prevents this degradation and maintains normal cytoarchitecture.
  • a method for stimulating the formation of an inner ear sensory hair cell from an inner ear support cell comprising damaging a first inner ear sensory hair cell under conditions that promote the formation of one or more new inner ear sensory hair cells from a support cell that is in contact with the damaged, first inner ear sensory hair cell.
  • a method for improving auditory function in an inner ear comprising:
  • step (b) measuring an improvement in auditory function in the inner ear treated in accordance with step (a).
  • a method for stimulating the formation of an inner ear support cell comprising damaging a first inner ear support cell under conditions that promote the formation of one or more new inner ear support cells.
  • the first inner ear support cell is selected from the group consisting of Hensen's cells, Deiter's cells, inner Pillar cells, border cells and outer Pillar cells.
  • a method for improving auditory function in an inner ear comprising:

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Analytical Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2001/021793 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear WO2002004605A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001288219A AU2001288219C1 (en) 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear
AU8821901A AU8821901A (en) 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear
JP2002509459A JP2004502785A (ja) 2000-07-11 2001-07-10 内耳における細胞の再生および分化の刺激
CN018126065A CN1441841B (zh) 2000-07-11 2001-07-10 对内耳的细胞再生和分化的刺激
EP01967939A EP1307542A2 (en) 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear
CA2412764A CA2412764C (en) 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear
KR1020037000388A KR100896489B1 (ko) 2000-07-11 2001-07-10 내이에서 세포 재생 및 분화의 자극

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61409900A 2000-07-11 2000-07-11
US09/614,099 2000-07-11

Publications (2)

Publication Number Publication Date
WO2002004605A2 true WO2002004605A2 (en) 2002-01-17
WO2002004605A3 WO2002004605A3 (en) 2003-02-27

Family

ID=24459860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021793 WO2002004605A2 (en) 2000-07-11 2001-07-10 Stimulation of cellular regeneration and differentiation in the inner ear

Country Status (7)

Country Link
EP (1) EP1307542A2 (zh)
JP (1) JP2004502785A (zh)
KR (1) KR100896489B1 (zh)
CN (1) CN1441841B (zh)
AU (2) AU8821901A (zh)
CA (1) CA2412764C (zh)
WO (1) WO2002004605A2 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095338A1 (de) * 2010-02-08 2011-08-11 Emc Microcollections Gmbh Neue aminoalkyl-oxazol- und aminoalkyl-thiazolcarbonsäureamide als regenerationsfördernde substanzen für sinnesorgane und postmitotische gewebe
WO2013106494A1 (en) * 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
EP2739637A1 (en) * 2011-08-03 2014-06-11 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide compounds for treating hearing and balance disorders
US11274273B2 (en) 2005-07-26 2022-03-15 Corning Incorporated Multilayered cell culture apparatus
WO2022147891A1 (zh) * 2021-01-07 2022-07-14 中国科学院脑科学与智能技术卓越创新中心 异位联合过表达Atoh1和Ikzf2再生耳蜗外毛细胞及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2092052B1 (en) 2006-12-07 2020-09-23 Wilson Wolf Manufacturing Corporation Highly efficient gas permeable devices for culturing cells
JP7080173B2 (ja) 2016-01-29 2022-06-03 マサチューセッツ アイ アンド イヤー インファーマリー 内耳支持細胞の拡大および分化ならびにその使用法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023084A1 (en) 1998-10-21 2000-04-27 Jonathan Kil Methods for stimulating the regeneration of inner ear cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593290B1 (en) * 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023084A1 (en) 1998-10-21 2000-04-27 Jonathan Kil Methods for stimulating the regeneration of inner ear cells

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
COLLUM, R.G. ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, no. 18, 1992, pages 4919 - 4925
ERKMAN, L., NATURE, vol. 381, no. 6583, 1996, pages 603 - 606
GERRERO ET AL., PROC. NAT'L. ACAD. SCI. (U.S.A., vol. 90, no. 22, 1993, pages 10841 - 10845
GRAY'S ANATOMY: "Revised American", 1977, pages: 859 - 867
LALWANI, A. K. ET AL., HEARING RESEARCH, vol. 114, 1997, pages 139 - 147
VAHAVA,O., SCIENCE, vol. 279, no. 5358, 1998, pages 1950 - 1954
XIANG ET AL., NEURON, vol. 11, 1993, pages 689 - 701
XIANG, M. ET AL., J. NEUROSCI., vol. 15, no. 7-1, 1995, pages 4762 - 4785
XIANG, M. ET AL., PROC. NAT'L. ACAD. SCI. (U.S.A., vol. 93, no. 21, 1996, pages 11950 - 11955
XIANG, M. ET AL., PROC. NAT'L. ACAD. SCO. (U.S.A., vol. 94, no. 17, 1997, pages 9445 - 9450

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274273B2 (en) 2005-07-26 2022-03-15 Corning Incorporated Multilayered cell culture apparatus
US11905506B2 (en) 2005-07-26 2024-02-20 Corning Incorporated Multilayered cell culture apparatus
WO2011095338A1 (de) * 2010-02-08 2011-08-11 Emc Microcollections Gmbh Neue aminoalkyl-oxazol- und aminoalkyl-thiazolcarbonsäureamide als regenerationsfördernde substanzen für sinnesorgane und postmitotische gewebe
US8889723B2 (en) 2010-02-08 2014-11-18 Emc Microcollections Gmbh Aminoalkyloxazole and aminoalkylthiazolecarboxylic acid amides as regeneration-promoting substances for sensory organs and post-mitotic tissues
EP2739637A1 (en) * 2011-08-03 2014-06-11 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide compounds for treating hearing and balance disorders
EP2739637A4 (en) * 2011-08-03 2015-04-22 Quark Pharmaceuticals Inc DOUBLE-STRONG OLIGONUCLEOTIDE COMPOUNDS FOR THE TREATMENT OF HEARING AND BALANCE OF IMPAIRMENT
WO2013106494A1 (en) * 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
CN104080912A (zh) * 2012-01-12 2014-10-01 夸克制药公司 用于治疗听力和平衡障碍的组合疗法
US9434946B2 (en) 2012-01-12 2016-09-06 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
WO2022147891A1 (zh) * 2021-01-07 2022-07-14 中国科学院脑科学与智能技术卓越创新中心 异位联合过表达Atoh1和Ikzf2再生耳蜗外毛细胞及其应用

Also Published As

Publication number Publication date
KR100896489B1 (ko) 2009-05-08
JP2004502785A (ja) 2004-01-29
CN1441841A (zh) 2003-09-10
AU2001288219B2 (en) 2006-11-23
EP1307542A2 (en) 2003-05-07
CN1441841B (zh) 2013-03-20
AU8821901A (en) 2002-01-21
CA2412764A1 (en) 2002-01-17
AU2001288219B9 (en) 2009-11-19
KR20030046386A (ko) 2003-06-12
CA2412764C (en) 2014-06-03
AU2001288219C1 (en) 2009-12-03
WO2002004605A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
US20230112986A1 (en) Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US7741303B2 (en) Stimulation of cellular regeneration and differentiation in the inner ear
US10494636B2 (en) Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease
US20220071915A1 (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
US11571463B2 (en) Polynucleotides encoding interleukin-12 (IL12) and uses thereof
AU2017266948B2 (en) Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
EP3458105B1 (en) Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
US12128113B2 (en) Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
AU2013312305B2 (en) Methods and compositions for regenerating hair cells and/or supporting cells
US20190298657A1 (en) Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
CA2298414C (en) Method for preventing and treating hearing loss using a neurturin protein product
JP2020520640A (ja) 連結したインターロイキン−１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチド及びその使用
AU2016369612A1 (en) Polynucleotides encoding methylmalonyl-CoA mutase
US20190382774A1 (en) Polyribonucleotides containing reduced uracil content and uses thereof
BR112020012555A2 (pt) composições de vcar e métodos para uso
AU2001288219B9 (en) Stimulation of cellular regeneration and differentiation in the inner ear
WO2023051802A1 (zh) 直接转分化治疗神经系统疾病
CA3112398A1 (en) Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2000023084A1 (en) Methods for stimulating the regeneration of inner ear cells
US20220008433A1 (en) Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells
JP5090645B2 (ja) 神経細胞移植補助剤および移植用神経細胞の製造法
KR20230005843A (ko) 피부 당뇨병성 다발신경병증의 관리를 위한 신경성 조직 나노형질주입
TW201139675A (en) NeuroD1 gene expression in non-endocrine pancreatic epithelial cells (NEPECs)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2412764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001288219

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020037000388

Country of ref document: KR

Ref document number: 018126065

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001967939

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001967939

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037000388

Country of ref document: KR